Navigating the “MACE” in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits-Reference-Cited by-同舟云学术

Navigating the “MACE” in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits

Published:2019-08 Issue:8 Volume:21 Page:1780-1789
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Hupfeld Christopher¹²,Mudaliar Sunder¹²

Affiliation:

1. Endocrinology/Diabetes Section, Veterans Affairs Medical Centre San Diego California

2. Endocrinology Division, Department of Medicine, University of California, San Diego School of Medicine San Diego California

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13740

Reference49 articles.

1. Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus

2. Effects of Intensive Glucose Lowering in Type 2 Diabetes

3. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

4. US Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet].www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed April 14 2019.

5. Usefulness of quantitative and qualitative angiographic lesion morphology, and clinical characteristics in predicting major adverse cardiac events during and after native coronary balloon angioplasty

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series;Clinical Case Reports;2024-09

2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE);Clinical Drug Investigation;2024-03-20

3. Diabetes Remission - The Holy Grail in Diabetes Management;Chronicle of Diabetes Research and Practice;2024-01

4. Evolution of Cardiovascular Outcomes Studies;Contemporary Cardiology;2024

5. Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus—A Real-Life Clinical Practice Study;Biomedicines;2023-09-04